The LOXL2 protein plays a critical role in the development of idiopathic pulmonary fibrosis (IPF) by helping promote lung tissue scarring, according to a study. LOXL2 is one of a family of proteins important to extracellular matrix (ECM), a non-cell component essential for providing structural and biochemical support to tissues and organs. LOXL2…
News
The Pulmonary Fibrosis Foundation (PFF), a trusted resource for the estimated 200,000 Americans with pulmonary fibrosis (PF), has published its new “Pulmonary Fibrosis Information Guide“ — which gives patients, family members and healthcare providers a better understanding of PF as well as idiopathic pulmonary fibrosis (IPF). The 36-page guide, available online here and…
Broadway stars at New York City’s Edison Ballroom helped raised a record $250,000 to support the battle against pulmonary fibrosis (PF) in the 7th annual ‘Broadway Belts for PFF!’ To help boost funding for PF research, actress and dedicated Pulmonary Fibrosis Foundation (PFF) advocate Julie Halston hosted the benefit show, which featured Grammy and Tony award winners. Halston…
Clinical trial results indicate that inhaled TD139 is an effective, safe and well-tolerated treatment for idiopathic pulmonary fibrosis (IPF), its maker, Galecto Biotech AB, has reported. The phase 1b/2a clinical trial (NCT02257177) was divided into two parts. Part 1 was a randomized, double-blind, single-center, placebo-controlled, single ascending dose phase 1…
Synairgen released further positive data from its lysyl oxidase-like 2 enzyme (LOXL2) inhibitor program to treat idiopathic pulmonary fibrosis (IPF), being conducted in collaboration with Pharmaxis. A Phase 1 clinical trial is set to start this year, if toxicology studies are successfully completed. Synairgen and Pharmaxis entered a collaboration in August…
Shorter telomeres — the DNA regions that protect the ends of chromosomes — are linked to lower survival rates in pulmonary fibrosis (PF) patients who receive a lung transplant. These patients’ lungs start failing sooner than those of other patients, suggesting that telomere length may be a factor to consider…
A molecular cascade that prompts stem cells used in lung transplants to drive fibrotic processes is responsible for the low survival rates of patients who obtain transplants, according to a study. The research also identified potential treatments to slow the fibrosis or scarring process. The good news is that is that the…
When patients with idiopathic pulmonary fibrosis (IPF) get involved in treatment decisions, it is likely to increase the dialogue between them and their doctors, according to a global survey supported by Boehringer Ingelheim. A key survey finding was that two of three IPF patients are involved in treatment decisions.
Researchers discovered a molecule that promotes lung fibrosis by integrating large amounts of data from patients, cell experiments, and animal models. They also used a big data approach to identify a potential treatment that targets the factor — a cancer therapy that is already in clinical trials. The study,…
A new Mayo Clinic study has demonstrated new evidence of the link between the biology of aging and idiopathic pulmonary fibrosis (IPF). The study, “Cellular senescence mediates fibrotic pulmonary disease,” appeared in this month’s issue of Nature Communications and point towards new possible directions for therapies targeting IPF. “Idiopathic pulmonary fibrosis…
